STRM.BIO
PrivateLast Round
Series Seed
2
Jan 7, 2026
Total Funding Raised
$18.66M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
STRM.BIO operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series Seed 2 round in January 2026.
STRM.BIO is a biotechnology company that is developing a proprietary extracellular vesicle (EV) platform to deliver gene therapies directly to patients.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
STRM.BIO Comparables
Compare STRM.BIO with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Carmine Therapeutics | 91% | |
| AGS Therapeutics | 85% | |
| Code Biotherapeutics | 84% |
For institutional investors. Book with your work email.
STRM.BIO Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series Seed 2 | Jan 7, 2026 | ||||
| Grant | Dec 3, 2025 | ||||
| Grant | Oct 3, 2023 | ||||
| Grant | Jul 26, 2022 | ||||
| Seed | Mar 31, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
STRM.BIO Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ascension Ventures | Seed |
| The Engine | Seed |
| NIH RADx | Grant |
| Gaingels | Seed |
| Alix Ventures | Seed |
| Gates Foundation | Grant |
| Breakout Ventures | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 7, 2026
Raised $8M led by Recordati SpA.
- Dec 3, 2025
Raised $8M in Series Seed 2 funding.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 16, 2026
In 2024, STRM.BIO, Incorporated hires Michael Luther as CEO in Massachusetts to reset the gene therapy startup after it exhausts its cash reserves.
For institutional investors. Book with your work email.
STRM.BIO Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about STRM.BIO's valuation, stock price, and market status.
Is STRM.BIO a public or private company?
STRM.BIO is a private company.
What is the current stock price of STRM.BIO?
STRM.BIO is a private company, so its shares have no public market price. Caplight tracks STRM.BIO's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is STRM.BIO worth (valuation)?
Valuation information for STRM.BIO is not publicly available.
Can I buy STRM.BIO stock?
STRM.BIO shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was STRM.BIO's last funding round?
STRM.BIO's most recent funding round was Series Seed 2 on January 7, 2026.
Who are the main investors in STRM.BIO?
Key investors in STRM.BIO include Ascension Ventures, The Engine, NIH RADx, Gaingels, Alix Ventures.
Will STRM.BIO IPO soon?
No public IPO plans have been announced for STRM.BIO.
How can I track STRM.BIO secondary market activity?
Caplight tracks bids, offers, and trades in STRM.BIO's shares on secondary markets.